Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
{(4Z)-2-[(1R,2R)-1-Amino–hydroxypropyl]-4–(amino–indol–methylene)–5–oxo–dihydroimidazol–acetic acid is a synthetic small molecule with the molecular formula C17H19N5O4 and a monoisotopic mass of approximately 357.14 g/mol[7][5]. It is listed in DrugBank as an experimental compound (DB01641), but there are no approved indications or clinical trials associated with it[8][5]. The structure features an imidazole ring substituted with both amino and indole groups. No mechanism of action or pharmacological activity has been reported in public databases. There are no known brand names or marketed products containing this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on {(4Z)-2-[(1R,2R)-1-Amino-2-hydroxypropyl]-4-[(4-amino-1H-indol-3-yl)methylene]-5-oxo-4,5-dihydro-1H-imidazol-1-yl}acetic acid.